ATLANTA--Richard E. Perlman, Executive Chairman and James K. Price, Chief Executive Officer of ExamWorks Group, Inc. (NYSE:EXAM), will present at the Bank of America Merrill Lynch 2014 Leveraged Finance Conference in Boca Raton, Florida on Tuesday, December 2nd at 4:50 p.m.
AUSTIN, Texas--LDR Holding Corporation (Nasdaq:LDRH), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, today announced that management will be participating in the following investment conferences in New York, NY:
SAN CLEMENTE, Calif.--ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, today announced that Company management will be presenting at the Piper Jaffray 26th Annual Healthcare Conference to be held on December 2-3, 2014, at The New York Palace in NYC.
BERKLEY HEIGHTS, N.J.--Authentidate Holding Corp. (Nasdaq:ADAT), a provider of secure web-based software applications and telehealth products and services for healthcare organizations, today announced that Mr. O'Connell "Ben" Benjamin, Chief Executive Officer, will present at the LD Micro Conference at 11:30 a.m. (PT), Track 2, on Wednesday, December 3, 2014.
REDWOOD CITY, Calif.--Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, announced that results from the pivotal Phase 3 program of the company's lead product candidate, Patiromer for Oral Suspension (Patiromer FOS), were published today in New England Journal of Medicine.
COPPELL, Texas--ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the publication of previously unreleased detailed results from the ZS003 study in the New England Journal of Medicine (NEJM).
DRAPER, Utah--HealthEquity, Inc. (Nasdaq:HQY), one of the largest HSA non-bank custodians, today announced that the company will release the results for its third quarter ended October 31, 2014 after the market closes on Tuesday, December 9, 2014.
GREENVILLE, S.C.--Midwest Advanced Radiology Center (MRAD), a multi-modality outpatient imaging facility with two locations in the northern Chicago suburbs, has deployed a comprehensive suite of eRAD solutions to automate its business and clinical workflow.
SILVER SPRING, Md.--Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today Nuvilex's Chief Executive Officer, Kenneth L. Waggoner, and Chief Operating Officer, Gerald W. Crabtree, Ph.D., are in Singapore to finalize the Diabetes Consortium that will develop a treatment for insulin dependent diabetes, to negotiate an additional worldwide, exclusive license to use Cell-in-a-Box® live cell encapsulation with cannabinoids to treat diseases and related symptoms and to tour the new facilities of Austrianova in Singapore.
Amsterdam, The Netherlands--uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that it will be hosting an Investor Day and simultaneous webcast in New York City on December 1, 2014, starting at 8:30 a.m. uniQure management will be joined by distinguished guests to discuss the Company's strategy, clinical programs and uniQure's vision of how gene therapy will change the future of medicine.
IRVINE, Calif.--Sabra Health Care REIT, Inc. (Nasdaq:SBRA) announced today that Harold W. Andrews Jr., the company's Chief Financial Officer, will present at the Bank of America-Merrill Lynch Leveraged Finance Conference on Tuesday, December 2, 2014 from 2:50 to 3:20 pm Eastern Time.
IRVINE, Calif.--Sabra Health Care REIT, Inc. (Nasdaq:SBRA) (Nasdaq:SBRAP) announced today that Rick Matros, the Company's Chairman and Chief Executive Officer and Talya Nevo-Hacohen, the Company's Chief Investment Officer, will be participating in a non-deal roadshow hosted by Bank of America – Merrill Lynch on December 2 – 3, 2014 in New York, New York and Boston, Massachusetts.
NEW YORK--Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today presented additional results from ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects (trial Part 1) and in patients with dementia, including Alzheimer's disease (trial Part 2).
MORRIS PLAINS, N.J.--Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan status for the use of veltuzumab, the Company's humanized anti-CD20 antibody, for the treatment of pemphigus.